Cover Image
市場調查報告書

肝斑:開發中產品分析

Melasma (Chlosma) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 360904
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
肝斑:開發中產品分析 Melasma (Chlosma) - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 30 Pages
簡介

本報告提供肝斑治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

肝斑概要

治療藥的開發

  • 開發中產品的概要

肝斑:企業開發中的治療藥

肝斑:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

肝斑:企業開發中的產品

肝斑治療藥的開發企業

  • EpiPharm AG
  • Hyundai Pharmaceutical Co., Ltd.
  • RXi Pharmaceuticals Corporation

肝斑:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肝斑:最近的開發平台趨勢

肝斑:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8701IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melasma (Chlosma) - Pipeline Review, H2 2016, provides an overview of the Melasma (Chlosma) (Dermatology) pipeline landscape.

Melasma is a common skin problem. The condition causes dark, discolored patches on your skin. The dark patches in melasma could be triggered by several factors, including pregnancy, birth control pills, hormone replacement therapy (HRT and progesterone), family history of melasma, race, antiseizure medications, and other medications that make the skin more prone to pigmentation after exposure to ultraviolet (UV) light.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melasma (Chlosma) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melasma (Chlosma) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melasma (Chlosma) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Melasma (Chlosma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 1 and 2 respectively.Melasma (Chlosma).

Melasma (Chlosma) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melasma (Chlosma) (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Melasma (Chlosma) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melasma (Chlosma) (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melasma (Chlosma) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melasma (Chlosma) (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melasma (Chlosma) (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melasma (Chlosma) (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 3
  • List of Figures 3
  • Introduction 4
  • Global Markets Direct Report Coverage 4
  • Melasma (Chlosma) Overview 5
  • Therapeutics Development 6
  • Pipeline Products for Melasma (Chlosma) - Overview 6
  • Melasma (Chlosma) - Therapeutics under Development by Companies 7
  • Melasma (Chlosma) - Pipeline Products Glance 8
  • Clinical Stage Products 8
  • Early Stage Products 9
  • Melasma (Chlosma) - Products under Development by Companies 10
  • Melasma (Chlosma) - Companies Involved in Therapeutics Development 11
  • EpiPharm AG 11
  • Hyundai Pharmaceutical Co Ltd 12
  • RXi Pharmaceuticals Corp 13
  • Melasma (Chlosma) - Therapeutics Assessment 14
  • Assessment by Monotherapy Products 14
  • Assessment by Target 15
  • Assessment by Mechanism of Action 17
  • Assessment by Route of Administration 19
  • Assessment by Molecule Type 21
  • Drug Profiles 23
  • EPI-M13 - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • NPH-29 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • tranexamic acid - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • TRY-26071 - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • TRY-26077 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • Melasma (Chlosma) - Dormant Projects 28
  • Appendix 29
  • Methodology 29
  • Coverage 29
  • Secondary Research 29
  • Primary Research 29
  • Expert Panel Validation 29
  • Contact Us 29
  • Disclaimer 30

List of Tables

  • Number of Products under Development for Melasma (Chlosma), H2 2016 6
  • Number of Products under Development by Companies, H2 2016 7
  • Comparative Analysis by Clinical Stage Development, H2 2016 8
  • Comparative Analysis by Early Stage Development, H2 2016 9
  • Products under Development by Companies, H2 2016 10
  • Melasma (Chlosma) - Pipeline by EpiPharm AG, H2 2016 11
  • Melasma (Chlosma) - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2016 12
  • Melasma (Chlosma) - Pipeline by RXi Pharmaceuticals Corp, H2 2016 13
  • Assessment by Monotherapy Products, H2 2016 14
  • Number of Products by Stage and Target, H2 2016 16
  • Number of Products by Stage and Mechanism of Action, H2 2016 18
  • Number of Products by Stage and Route of Administration, H2 2016 20
  • Number of Products by Stage and Molecule Type, H2 2016 22
  • Melasma (Chlosma) - Dormant Projects, H2 2016 28

List of Figures

  • Number of Products under Development for Melasma (Chlosma), H2 2016 6
  • Number of Products under Development by Companies, H2 2016 7
  • Comparative Analysis by Early Stage Products, H2 2016 9
  • Assessment by Monotherapy Products, H2 2016 14
  • Number of Products by Targets, H2 2016 15
  • Number of Products by Stage and Targets, H2 2016 15
  • Number of Products by Mechanism of Actions, H2 2016 17
  • Number of Products by Stage and Mechanism of Actions, H2 2016 17
  • Number of Products by Routes of Administration, H2 2016 19
  • Number of Products by Stage and Routes of Administration, H2 2016 19
  • Number of Products by Molecule Types, H2 2016 21
  • Number of Products by Stage and Molecule Types, H2 2016 21
Back to Top